CRANE CO (CR) Fundamental Analysis & Valuation

NYSE:CR • US2244081046

Current stock price

191.69 USD
+3.23 (+1.71%)
Last:

This CR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. CR Profitability Analysis

1.1 Basic Checks

  • In the past year CR was profitable.
  • CR had a positive operating cash flow in the past year.
  • Each year in the past 5 years CR has been profitable.
  • Of the past 5 years CR 4 years had a positive operating cash flow.
CR Yearly Net Income VS EBIT VS OCF VS FCFCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • CR's Return On Assets of 9.51% is amongst the best of the industry. CR outperforms 81.68% of its industry peers.
  • CR has a Return On Equity of 17.79%. This is amongst the best in the industry. CR outperforms 83.97% of its industry peers.
  • CR has a better Return On Invested Capital (9.76%) than 72.52% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for CR is in line with the industry average of 10.01%.
Industry RankSector Rank
ROA 9.51%
ROE 17.79%
ROIC 9.76%
ROA(3y)10.52%
ROA(5y)11.62%
ROE(3y)18.21%
ROE(5y)23.2%
ROIC(3y)11.11%
ROIC(5y)9.19%
CR Yearly ROA, ROE, ROICCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • CR has a Profit Margin of 15.90%. This is amongst the best in the industry. CR outperforms 91.60% of its industry peers.
  • In the last couple of years the Profit Margin of CR has grown nicely.
  • With an excellent Operating Margin value of 18.40%, CR belongs to the best of the industry, outperforming 85.50% of the companies in the same industry.
  • CR's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 42.20%, CR belongs to the top of the industry, outperforming 80.15% of the companies in the same industry.
  • CR's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 18.4%
PM (TTM) 15.9%
GM 42.2%
OM growth 3Y24.93%
OM growth 5Y11.9%
PM growth 3Y-11.02%
PM growth 5Y20.88%
GM growth 3Y4.28%
GM growth 5Y4.26%
CR Yearly Profit, Operating, Gross MarginsCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CR Health Analysis

2.1 Basic Checks

  • CR has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, CR has more shares outstanding
  • The number of shares outstanding for CR has been reduced compared to 5 years ago.
  • Compared to 1 year ago, CR has a worse debt to assets ratio.
CR Yearly Shares OutstandingCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CR Yearly Total Debt VS Total AssetsCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • CR has an Altman-Z score of 5.82. This indicates that CR is financially healthy and has little risk of bankruptcy at the moment.
  • CR's Altman-Z score of 5.82 is amongst the best of the industry. CR outperforms 80.92% of its industry peers.
  • CR has a debt to FCF ratio of 3.36. This is a good value and a sign of high solvency as CR would need 3.36 years to pay back of all of its debts.
  • CR has a Debt to FCF ratio of 3.36. This is in the better half of the industry: CR outperforms 64.89% of its industry peers.
  • CR has a Debt/Equity ratio of 0.56. This is a neutral value indicating CR is somewhat dependend on debt financing.
  • CR has a Debt to Equity ratio (0.56) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 3.36
Altman-Z 5.82
ROIC/WACC0.95
WACC10.23%
CR Yearly LT Debt VS Equity VS FCFCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 5.53 indicates that CR has no problem at all paying its short term obligations.
  • CR has a better Current ratio (5.53) than 92.37% of its industry peers.
  • CR has a Quick Ratio of 4.72. This indicates that CR is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 4.72, CR belongs to the best of the industry, outperforming 93.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.53
Quick Ratio 4.72
CR Yearly Current Assets VS Current LiabilitesCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. CR Growth Analysis

3.1 Past

  • CR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.05%, which is quite good.
  • The Earnings Per Share has been growing by 9.48% on average over the past years. This is quite good.
  • The Revenue has grown by 8.16% in the past year. This is quite good.
  • The Revenue has been decreasing by -4.73% on average over the past years.
EPS 1Y (TTM)17.05%
EPS 3Y-7.77%
EPS 5Y9.48%
EPS Q2Q%21.43%
Revenue 1Y (TTM)8.16%
Revenue growth 3Y9.07%
Revenue growth 5Y-4.73%
Sales Q2Q%6.78%

3.2 Future

  • CR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.63% yearly.
  • The Revenue is expected to grow by 9.30% on average over the next years. This is quite good.
EPS Next Y13.91%
EPS Next 2Y13.5%
EPS Next 3Y13.69%
EPS Next 5Y12.63%
Revenue Next Year24.84%
Revenue Next 2Y14.96%
Revenue Next 3Y11.55%
Revenue Next 5Y9.3%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CR Yearly Revenue VS EstimatesCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
CR Yearly EPS VS EstimatesCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

3

4. CR Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 31.74, the valuation of CR can be described as expensive.
  • The rest of the industry has a similar Price/Earnings ratio as CR.
  • Compared to an average S&P500 Price/Earnings ratio of 26.86, CR is valued at the same level.
  • The Price/Forward Earnings ratio is 27.86, which means the current valuation is very expensive for CR.
  • CR's Price/Forward Earnings ratio is in line with the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 37.39, CR is valued a bit cheaper.
Industry RankSector Rank
PE 31.74
Fwd PE 27.86
CR Price Earnings VS Forward Price EarningsCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CR is valued a bit more expensive than the industry average as 67.18% of the companies are valued more cheaply.
  • CR's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 32.43
EV/EBITDA 24.29
CR Per share dataCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of CR may justify a higher PE ratio.
  • CR's earnings are expected to grow with 13.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.28
PEG (5Y)3.35
EPS Next 2Y13.5%
EPS Next 3Y13.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. CR Dividend Analysis

5.1 Amount

  • CR has a yearly dividend return of 0.51%, which is pretty low.
  • Compared to an average industry Dividend Yield of 1.07, CR has a dividend in line with its industry peers.
  • With a Dividend Yield of 0.51, CR pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.51%

5.2 History

  • The dividend of CR decreases each year by -11.69%.
  • CR has been paying a dividend for at least 10 years, so it has a reliable track record.
  • The dividend of CR decreased recently.
Dividend Growth(5Y)-11.69%
Div Incr Years1
Div Non Decr Years1
CR Yearly Dividends per shareCR Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5

5.3 Sustainability

  • CR pays out 14.43% of its income as dividend. This is a sustainable payout ratio.
DP14.43%
EPS Next 2Y13.5%
EPS Next 3Y13.69%
CR Yearly Income VS Free CF VS DividendCR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M
CR Dividend Payout.CR Dividend Payout, showing the Payout Ratio.CR Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

CR Fundamentals: All Metrics, Ratios and Statistics

CRANE CO

NYSE:CR (4/13/2026, 1:06:16 PM)

191.69

+3.23 (+1.71%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)01-26
Earnings (Next)04-27
Inst Owners76.61%
Inst Owner Change0.07%
Ins Owners0.29%
Ins Owner Change0.48%
Market Cap11.07B
Revenue(TTM)2.31B
Net Income(TTM)366.60M
Analysts83.33
Price Target223.29 (16.48%)
Short Float %1.24%
Short Ratio1.22
Dividend
Industry RankSector Rank
Dividend Yield 0.51%
Yearly Dividend0.92
Dividend Growth(5Y)-11.69%
DP14.43%
Div Incr Years1
Div Non Decr Years1
Ex-Date02-27
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.03%
Min EPS beat(2)5.05%
Max EPS beat(2)7.02%
EPS beat(4)4
Avg EPS beat(4)5.79%
Min EPS beat(4)3.28%
Max EPS beat(4)7.79%
EPS beat(8)8
Avg EPS beat(8)3.99%
EPS beat(12)12
Avg EPS beat(12)9.29%
EPS beat(16)15
Avg EPS beat(16)7.78%
Revenue beat(2)0
Avg Revenue beat(2)-1.29%
Min Revenue beat(2)-1.39%
Max Revenue beat(2)-1.18%
Revenue beat(4)0
Avg Revenue beat(4)-1.27%
Min Revenue beat(4)-1.39%
Max Revenue beat(4)-1.18%
Revenue beat(8)1
Avg Revenue beat(8)-1.11%
Revenue beat(12)3
Avg Revenue beat(12)-0.77%
Revenue beat(16)5
Avg Revenue beat(16)1.97%
PT rev (1m)0%
PT rev (3m)2.65%
EPS NQ rev (1m)0.26%
EPS NQ rev (3m)-2.02%
EPS NY rev (1m)0.01%
EPS NY rev (3m)1.09%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)6.49%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)17.06%
Valuation
Industry RankSector Rank
PE 31.74
Fwd PE 27.86
P/S 4.8
P/FCF 32.43
P/OCF 28.03
P/B 5.37
P/tB 9.02
EV/EBITDA 24.29
EPS(TTM)6.04
EY3.15%
EPS(NY)6.88
Fwd EY3.59%
FCF(TTM)5.91
FCFY3.08%
OCF(TTM)6.84
OCFY3.57%
SpS39.92
BVpS35.7
TBVpS21.26
PEG (NY)2.28
PEG (5Y)3.35
Graham Number69.65
Profitability
Industry RankSector Rank
ROA 9.51%
ROE 17.79%
ROCE 12.52%
ROIC 9.76%
ROICexc 11.47%
ROICexgc 16.14%
OM 18.4%
PM (TTM) 15.9%
GM 42.2%
FCFM 14.81%
ROA(3y)10.52%
ROA(5y)11.62%
ROE(3y)18.21%
ROE(5y)23.2%
ROIC(3y)11.11%
ROIC(5y)9.19%
ROICexc(3y)13.17%
ROICexc(5y)10.95%
ROICexgc(3y)22.21%
ROICexgc(5y)18.82%
ROCE(3y)14.25%
ROCE(5y)11.94%
ROICexgc growth 3Y37.68%
ROICexgc growth 5Y-3.77%
ROICexc growth 3Y36.16%
ROICexc growth 5Y9.91%
OM growth 3Y24.93%
OM growth 5Y11.9%
PM growth 3Y-11.02%
PM growth 5Y20.88%
GM growth 3Y4.28%
GM growth 5Y4.26%
F-Score6
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 3.36
Debt/EBITDA 2.42
Cap/Depr 106.57%
Cap/Sales 2.32%
Interest Coverage 54.38
Cash Conversion 83.22%
Profit Quality 93.1%
Current Ratio 5.53
Quick Ratio 4.72
Altman-Z 5.82
F-Score6
WACC10.23%
ROIC/WACC0.95
Cap/Depr(3y)96.17%
Cap/Depr(5y)95.85%
Cap/Sales(3y)2.04%
Cap/Sales(5y)1.94%
Profit Quality(3y)81.38%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.05%
EPS 3Y-7.77%
EPS 5Y9.48%
EPS Q2Q%21.43%
EPS Next Y13.91%
EPS Next 2Y13.5%
EPS Next 3Y13.69%
EPS Next 5Y12.63%
Revenue 1Y (TTM)8.16%
Revenue growth 3Y9.07%
Revenue growth 5Y-4.73%
Sales Q2Q%6.78%
Revenue Next Year24.84%
Revenue Next 2Y14.96%
Revenue Next 3Y11.55%
Revenue Next 5Y9.3%
EBIT growth 1Y19.22%
EBIT growth 3Y36.25%
EBIT growth 5Y6.6%
EBIT Next Year38%
EBIT Next 3Y18.93%
EBIT Next 5Y14.01%
FCF growth 1Y44.5%
FCF growth 3YN/A
FCF growth 5Y4.38%
OCF growth 1Y44.72%
OCF growth 3YN/A
OCF growth 5Y4.99%

CRANE CO / CR Fundamental Analysis FAQ

What is the fundamental rating for CR stock?

ChartMill assigns a fundamental rating of 6 / 10 to CR.


Can you provide the valuation status for CRANE CO?

ChartMill assigns a valuation rating of 3 / 10 to CRANE CO (CR). This can be considered as Overvalued.


How profitable is CRANE CO (CR) stock?

CRANE CO (CR) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for CR stock?

The Price/Earnings (PE) ratio for CRANE CO (CR) is 31.74 and the Price/Book (PB) ratio is 5.37.


How financially healthy is CRANE CO?

The financial health rating of CRANE CO (CR) is 7 / 10.